SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration: 1-Year Results

被引：23
作者：
Wykoff, Charles C.
Brown, David M.
Chen, Eric
Major, James C.
Croft, Daniel E.
Mariani, Angeline
Wong, Tien P.
机构：
[1] Retina Consultants of Houston, Methodist Hospital, Houston, TX 77030
来源：
OPHTHALMIC SURGERY LASERS & IMAGING | 2013年 / 44卷 / 02期
关键词：
TRAP-EYE;
D O I：
10.3928/23258160-20130313-04
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
OBJECTIVES: To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD). METHODS: Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments. RESULTS: Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03). CONCLUSION: Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.
引用
收藏
页码：121 / 126
页数：6
相关论文
共 15 条
[1]   Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients [J].
Brown, David M. ;
Regillo, Carl D. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 144 (04) :627-637
[2]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[3]   Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration-Primary End Point [J].
Brown, David M. ;
Chen, Eric ;
Mariani, Angeline ;
Major, James C., Jr. .
OPHTHALMOLOGY, 2013, 120 (02) :349-354
[4]  
Busbee BG, 2013, OPHTHALMOLOGY, DOI [10.1016/j.oph-tha.2012.10.014, DOI 10.1016/J.0PH-THA.2012.10.014]
[5]  
Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
[6]   Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [J].
Fung, A. T. ;
Kumar, N. ;
Vance, S. K. ;
Slakter, J. S. ;
Klancnik, J. M. ;
Spaide, R. S. ;
Freund, K. B. .
EYE, 2012, 26 (09) :1181-1187
[7]   NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS [J].
Gregori, Ninel Z. ;
Feuer, William ;
Rosenfeld, Philip J. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (07) :1046-1050
[8]   Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration [J].
Heier, Jeffrey S. ;
Brown, David M. ;
Chong, Victor ;
Korobelnik, Jean-Francois ;
Kaiser, Peter K. ;
Quan Dong Nguyen ;
Kirchhof, Bernd ;
Ho, Allen ;
Ogura, Yuichiro ;
Yancopoulos, George D. ;
Stahl, Neil ;
Vitti, Robert ;
Berliner, Alyson J. ;
Soo, Yuhwen ;
Anderesi, Majid ;
Groetzbach, Georg ;
Sommerauer, Bernd ;
Sandbrink, Rupert ;
Simader, Christian ;
Schmidt-Erfurth, Ursula .
OPHTHALMOLOGY, 2012, 119 (12) :2537-2548
[9]   The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing [J].
Heier, Jeffrey S. ;
Boyer, David ;
Quan Dong Nguyen ;
Marcus, Dennis ;
Roth, Daniel B. ;
Yancopoulos, George ;
Stahl, Neil ;
Ingerman, Avner ;
Vitti, Robert ;
Berliner, Alyson J. ;
Yang, Ke ;
Brown, David M. .
OPHTHALMOLOGY, 2011, 118 (06) :1098-1106
[10]   Medical progress: Age-related macular degeneration [J].
Jager, Rama D. ;
Mieler, William F. ;
Miller, Joan W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2606-2617
12